1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: S1P Receptor Modulator Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. S1P Receptor Modulator Drugs Market Revenue and Volume Forecast, by Application
8.1.1. Multiple Sclerosis
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Cardiovascular Diseases
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Transplant Rejection
8.1.3.1. Market Revenue and Volume Forecast
9.1. S1P Receptor Modulator Drugs Market Revenue and Volume Forecast, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Topical
9.1.3.1. Market Revenue and Volume Forecast
10.1. S1P Receptor Modulator Drugs Market Revenue and Volume Forecast, by Drug Class
10.1.1. Sphingosine 1-Phosphate Receptor Modulators
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Immunomodulators
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Antiproliferatives
10.1.3.1. Market Revenue and Volume Forecast
11.1. S1P Receptor Modulator Drugs Market Revenue and Volume Forecast, by Patient Type
11.1.1. Pediatric
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Adult
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Geriatric
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Application
12.1.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.3. Market Revenue and Volume Forecast, by Drug Class
12.1.4. Market Revenue and Volume Forecast, by Patient Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Application
12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.3. Market Revenue and Volume Forecast, by Drug Class
12.1.5.4. Market Revenue and Volume Forecast, by Patient Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Application
12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.3. Market Revenue and Volume Forecast, by Drug Class
12.1.6.4. Market Revenue and Volume Forecast, by Patient Type
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Application
12.2.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.3. Market Revenue and Volume Forecast, by Drug Class
12.2.4. Market Revenue and Volume Forecast, by Patient Type
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Application
12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.3. Market Revenue and Volume Forecast, by Drug Class
12.2.5.4. Market Revenue and Volume Forecast, by Patient Type
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Application
12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.3. Market Revenue and Volume Forecast, by Drug Class
12.2.6.4. Market Revenue and Volume Forecast, by Patient Type
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Application
12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.3. Market Revenue and Volume Forecast, by Drug Class
12.2.7.4. Market Revenue and Volume Forecast, by Patient Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Application
12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.3. Market Revenue and Volume Forecast, by Drug Class
12.2.8.4. Market Revenue and Volume Forecast, by Patient Type
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Application
12.3.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.3. Market Revenue and Volume Forecast, by Drug Class
12.3.4. Market Revenue and Volume Forecast, by Patient Type
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Application
12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.3. Market Revenue and Volume Forecast, by Drug Class
12.3.5.4. Market Revenue and Volume Forecast, by Patient Type
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Application
12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.3. Market Revenue and Volume Forecast, by Drug Class
12.3.6.4. Market Revenue and Volume Forecast, by Patient Type
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Application
12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.3. Market Revenue and Volume Forecast, by Drug Class
12.3.7.4. Market Revenue and Volume Forecast, by Patient Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Application
12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.3. Market Revenue and Volume Forecast, by Drug Class
12.3.8.4. Market Revenue and Volume Forecast, by Patient Type
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Application
12.4.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.3. Market Revenue and Volume Forecast, by Drug Class
12.4.4. Market Revenue and Volume Forecast, by Patient Type
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Application
12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.3. Market Revenue and Volume Forecast, by Drug Class
12.4.5.4. Market Revenue and Volume Forecast, by Patient Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Application
12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.3. Market Revenue and Volume Forecast, by Drug Class
12.4.6.4. Market Revenue and Volume Forecast, by Patient Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Application
12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.3. Market Revenue and Volume Forecast, by Drug Class
12.4.7.4. Market Revenue and Volume Forecast, by Patient Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Application
12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.3. Market Revenue and Volume Forecast, by Drug Class
12.4.8.4. Market Revenue and Volume Forecast, by Patient Type
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Application
12.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.3. Market Revenue and Volume Forecast, by Drug Class
12.5.4. Market Revenue and Volume Forecast, by Patient Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Application
12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.3. Market Revenue and Volume Forecast, by Drug Class
12.5.5.4. Market Revenue and Volume Forecast, by Patient Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Application
12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.3. Market Revenue and Volume Forecast, by Drug Class
12.5.6.4. Market Revenue and Volume Forecast, by Patient Type
13.1. Viatris
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Johnson & Johnson
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis International AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Idorsia Pharmaceuticals
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bristol Myers Squibb
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Mitsubishi Tanabe Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Sun Pharmaceutical Industries
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
